NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
13/06/2023
Voltar para busca
Dado oficial do USPTO
SAJAZIR
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
31
Atualização mais recente
13/06/2023
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
12/01/2021
Data de registro
13/06/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
13/06/2023
Última transação
13/06/2023
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
23/09/2022
Primeiro uso no comércio
23/09/2022
Código do desenho
4
Tipo de titular
99
Localização do titular
Cambridge, GB
Examinador
BRACEY, KAREN
Unidade examinadora
M70
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Cycle Pharmaceuticals Ltd.
Representantes
Mary Frances Love MUNCY, GEISSLER, OLDS & LOWE, P.C.
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical agents for the treatment of hereditary angioedemaall in the form of liquidstopical solutionsliquid suspensionssyrupsdropscapsulestabletscapletspowderscompressed tabletsdispersible tabletsinhaled vaporsgasesmiststopical creams and gelstransdermal patches; pharmaceutical preparations for the treatment of hereditary angioedemaall in the form of liquidstopical solutionsliquid suspensionssyrupsdropscapsulestabletscapletspowderscompressed tabletsdispersible tabletsinhaled vaporsgasesmiststopical creams and gelstransdermal patches; pharmaceuticals for the treatment of hereditary angioedema all in the form of liquidstopical solutionsliquid suspensionssyrupsdropscapsulestabletscapletspowderscompressed tabletsdispersible tabletsinhaled vaporsgasesmiststopical creams and gelstransdermal patches; Veterinary preparations for treatment of intestinal bacteria; veterinary preparationsantioxidants; veterinary preparationspain relief medications; veterinary preparations for medical treatment of chronic illnesses; veterinary preparations for treatment of viral diseases; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use; dietary supplements for humans and animals; supplements for the treatment of hereditary angioedema; supplements for the treatment of hereditary angioedemaall in the form of liquidstopical solutionsliquid suspensionssyrupsdropscapsulestabletscapletspowderscompressed tabletsdispersible tabletsinhaled vaporsgasesmiststopical creams and gelstransdermal patches; food for babies; medical dressings; plasters for medical purposes; material for stopping teethdental wax; disinfectants; preparations for destroying vermin; fungicidesherbicides; biological preparations for the treatment of hereditary angioedemaall in the form of liquidstopical solutionsliquid suspensionssyrupsdropscapsulestabletscapletspowderscompressed tabletsdispersible tabletsinhaled vaporsgasesmiststopical creams and gels and transdermal patches; chemical preparations for the medical treatment of hereditary angioedemaall in the form of liquidstopical solutionsliquid suspensionssyrupsdropscapsulestabletscapletspowderscompressed tabletsdispersible tabletsinhaled vaporsgasesmiststopical creams and gels and transdermal patches; Drug delivery agents consisting of liquidstopical solutionsliquid suspensionssyrupsdropscapsulestabletscapletspowderscompressed tabletsdispersible tabletsinhaled vaporsgasesmiststopical creams and gelstransdermal patches that facilitate delivery of a wide range of pharmaceuticals; drug delivery agents for use in pharmaceutical preparationsdrugs and medicines for the treatment of hereditary angioedemaall in the form of liquidstopical solutionsliquid suspensionssyrupsdropscapsulestabletscapletspowderscompressed tabletsdispersible tabletsinhaled vaporsgasesmiststopical creams and gelstransdermal patches; medical drugs for the treatment of rare diseasesin particular for the treatment of hereditary angioedemaall in the form of liquidstopical solutionsliquid suspensionssyrupsdropscapsulestabletscapletspowderscompressed tabletsdispersible tabletsinhaled vaporsgasesmiststopical creams and gelstransdermal patches; enzyme preparations for medical purposesenzyme preparations for the treatment of hereditary angioedemamedical enzyme preparations in the form of liquidstopical solutionsliquid suspensionssyrupsdropscapsulestabletscapletspowderscompressed tabletsdispersible tabletsinhaled vaporsgasesmiststopical creams and gelstransdermal patches; enzyme preparations for veterinary purposes; medicinal preparations for the treatment of hereditary angioedemaall in the form of liquidstopical solutionsliquid suspensionssyrupsdropscapsulestabletscapletspowderscompressed tabletsdispersible tabletsinhaled vaporsgasesmiststopical creams and gelstransdermal patches; medicines for the treatment of hereditary angioedemaall in the form of liquidstopical solutionsliquid suspensionssyrupsdropscapsulestabletscapletspowderscompressed tabletsdispersible tabletsinhaled vaporsgasesmiststopical creams and gelstransdermal patches; Medical and veterinary preparations and articlespre-filled syringes containing a bradykinin B2 receptor antagonist for medical purposes; Pharmaceuticals and natural remedy preparationsfor use in the treatment and management of hereditary angioedema; single-use pre-filled syringes containing a bradykinin B2 receptor antagonist; syringes sold filled with a bradykinin B2 receptor antagonist for subcutaneous injections in the treatment of acute attack of hereditary angioedema; single-use pre-filled syringes containing a bradykinin B2 receptor antagonist for subcutaneous injections in the treatment of acute attack of hereditary angioedema
Publicações
Histórico de despachos e eventos da marca no USPTO.
31 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
13/06/2023
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
09/05/2023
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
08/05/2023
SUPC
STATEMENT OF USE PROCESSING COMPLETE
04/05/2023
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
04/05/2023
IUAF
USE AMENDMENT FILED
18/04/2023
EISU
TEAS STATEMENT OF USE RECEIVED
18/04/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
18/10/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
23/08/2022
PUBO
PUBLISHED FOR OPPOSITION
23/08/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/08/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
15/07/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
14/07/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
14/07/2022
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
14/07/2022
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
01/02/2022
GNFR
FINAL REFUSAL E-MAILED
01/02/2022
CNFR
FINAL REFUSAL WRITTEN
01/02/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
20/01/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
20/01/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
20/01/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
05/08/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
05/08/2021
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
05/08/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
28/07/2021
GNRT
NON-FINAL ACTION E-MAILED
28/07/2021
CNRT
NON-FINAL ACTION WRITTEN
28/07/2021
DOCK
ASSIGNED TO EXAMINER
21/07/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/04/2021
NWAP
NEW APPLICATION ENTERED
15/01/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace SAJAZIR ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.